Body composition assessment by DEXA, BIA, or comparable methodology, at baseline and during treatment, makes lean mass loss visible
Retrieved from Wharton, S., Batterham, R
My take: Novo needed a clean win after months of ups/downs
A retrospective study conducted at the University Health Network found that, in liver transplant recipients with diabetes, combination therapy reduced HbA1c and alanine aminotransferase levels more effectively than DPP-4 inhibitors. Additionally, two clinical trials in patients with Type 2 diabetes demonstrated that combination therapy significantly lowered HbA1c by 1.34% and 1.21%, compared to a 0.54% reduction with placebo, starting from a baseline of 8.0%. These findings suggest that combination therapy may be especially beneficial in the liver transplant population, where patients often experience weight gain and develop metabolic co-morbidities
10mg 10mg
Brand names for semaglutide include Wegovy and Ozempic